Theralase to be Featured on CEO Clips

TORONTO, ON / ACCESSWIRE / June 30, 2016 / Theralase Technologies Inc. (“Theralase®” or the “Company“) (TSXV: TLT) (OTC: TLTFF), a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs“) to destroy cancer, announced today that the Company will be featured on CEO Clips on The Documentary Channel in Canada and on FOX Business News in the United States.

CEO Clips, a series which profiles the most innovative publicly traded companies in North America, will feature Theralase on The Documentary Channel and via a shorter version on Fox Business News.

Link: http://www.b-tv.com/theralase-commercial-2016/

In addition, the CEO Clips feature will be posted on the following financial portals: Business News Network – Finance, Thomson Reuters Inside Network, YouTube, BTV/CEO Clips and on Video News Release.

About Documentary Channel:

Documentary is a digital television station devoted to showing the best documentaries from Canada and around the world. With its special emphasis on feature length films, watching Documentary is like having a cinema in your own living room, showing award winning films twenty-four hours a day, seven days a week.

About FOX Business:

FOX Business was the largest launch in cable history and currently has 71 million subscribers. Its parent company, Fox News channel is the number one basic cable network for morning views, with 12 out of the top 15 business programs.

About Theralase Technologies Inc.

Theralase Technologies Inc. (“Theralase®” or the “Company“) (TSXV: TLT) (OTC: TLTFF) in its Therapeutic Laser Technology (“TLT“) Division designs, manufactures, markets and distributes patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase’s Photo Dynamic Therapy (“PDT“) Division researches and develops specially designed molecules called Photo Dynamic Compounds (“PDCs“), which are able to localize to cancer cells and then when laser light activated, effectively destroy them.

Additional information is available at www.theralase.com and www.sedar.com.

This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

Roger Dumoulin-White
President & CEO
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
rwhite@theralase.com
www.theralase.com

SOURCE: Theralase Technologies Inc.

ReleaseID: 441834